Source: Annual Congress 2006 - Pulmonary hypertension: diagnostic tools and therapeutic approaches
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
L. S. Mackay, J. O‘Sullivan, G. A. MacGowan, R. Allcock, A. J. Fisher, J. Lordan, P. A. Corris (Newcastle upon Tyne, United Kingdom). The effect of 12 months Bosentan treatment on congenital heart disease associated pulmonary arterial hypertension. Eur Respir J 2006; 28: Suppl. 50, 2489

Member's Comments

No comment yet.

Related content which might interest you: Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children Source: Eur Respir J 2011; 37: 70-77 Year: 2011 Effect of sitaxentan in patients with pulmonary arterial hypertension associated to congenital heart diseases Source: Annual Congress 2009 - Pulmonary vascular diseases Year: 2009 Initial experience of sildenafil in patients with congenital heart disease (CHD) associated pulmonary arterial hypertension (PAH) Source: Eur Respir J 2006; 28: Suppl. 50, 425s Year: 2006 Sildenafil effects on 1-year survival of patients with idiopathic pulmonary arterial hypertension (IPAH) Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005 Metformin added to bosentan therapy in patients with pulmonary arterial hypertension associated with congenital heart defects: a pilot study Source: ERJ Open Res, 4 (3) 00060-2018; 10.1183/23120541.00060-2018 Year: 2018 Pulmonary arterial hypertension in paediatric and adult patients with congenital heart disease Source: Eur Respir Rev 2009; 18: 154-161 Year: 2009 Bosentan treatment for pulmonary arterial hypertension related to congenital heart disease: real-world clinical experience in Spain Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009 Changing demographics of pulmonary arterial hypertension in congenital heart disease Source: Eur Respir Rev 2010 19: 308-313 Year: 2010 The endothelin-receptor antagonist bosentan for the treatment of pulmonary arterial hypertension (PAH) associated with congenital heart defects (CHD) Source: Annual Congress 2004 - Treatment of pulmonary hypertension Year: 2004 Nebulised Iloprost for pulmonary arterial hypertension associated with congenital heart disease: one centre's experience Source: Eur Respir J 2001; 18: Suppl. 33, 324s Year: 2001 Efficacy and safety of oral bosentan in patients with Down‘s syndrome and pulmonary arterial hypertension due to congenital heart disease Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH and associated PH Year: 2012 Pulmonary hypertension in children Source: Eur Respir Mon 2012; 57: 94-107 Year: 2012 The effects of beta-blocker therapy on heart rate, symptoms and exercise in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Double combination therapy in patients with pulmonary arterial hypertension associated with congenital heart defects Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Efficacy of exercise training in congenital heart disease associated pulmonary hypertension Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH and associated PH Year: 2012 Tadalafil in idiopathic or heritable pulmonary arterial hypertension compared to pulmonary arterial hypertension associated with connective tissue disease Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Age, risk and outcomes in idiopathic pulmonary arterial hypertension Source: Eur Respir J, 51 (5) 1800629; 10.1183/13993003.00629-2018 Year: 2018 Pulmonary arterial hypertension related with congenital heart disease (PAH r-CHD): a retrospective study of 21 patients Source: Annual Congress 2009 - Pulmonary circulation Year: 2009 Pulmonary arterial hypertension in children Source: Eur Respir J 2003; 21: 155-176 Year: 2003